Get started
PFIZER INCPFIZER INCPFIZER INC

PFIZER INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

DROPPING WELL AS EXPECTED. READY FOR THE 3RD BOOST? 👁️ 💉✅PREVIOUSLY ON PFE We were expecting that A was broken and it's broken. ✅ WHERE WE ARE Because A is broken, it's confirmed that 47.50 is B. If so, we should recognize the C, at which bearish 5 waves would be formed after B. As of now, 43.27(Fib61.8) looks like the good long entry point to ride the next boost. *As long as 37.96 remains unbroken, this idea is valid. 💡The absolute principle for trading💡 BUY - as low as possible SELL - as high as possible PLEASE DO NOT FORGET TO SMASH LIKE👍🏻 AND FOLLOW ME❤ IT MOTIVATES ME TO THE NEXT IDEA! THANK YOU 🎉
NYSE:PFE
by waveslover
PFIZER: FUNDAMENTAL ANALYSIS + NEXT TARGET POINT ⚡️As you know, Pfizer's biggest product at the moment is the coronavirus vaccine, Comirnati. The company and its partner BioNTech expect it to bring in more than $33 billion this year. Meanwhile, Pfizer expects revenue from the coronavirus vaccine to account for 42% of the company's total revenue. The vaccine is certainly one good reason to buy stock in this major pharmaceutical giant. But there is another reason to buy Pfizer stock, and it has nothing to do with the COVID-19 vaccine. It is important to remember that Pfizer has a huge number of commercialized products, including seven blockbuster drugs. Earlier this month, one of them received good news - news that should prompt us to take a closer look at this pharmaceutical company's stock. Eliquis, the blood-thinning drug commercialized by Pfizer and its partner Bristol Myers Squibb, received a very important decision in the appeals court. The court upheld the original decision protecting the patents on this best-selling drug, including the drug's composition and formula. This means that the generic drugmaker will not be able to enter the market with a competing drug until April 2028. Pfizer and Bristol Myers will probably file another appeal, but after two courts have already ruled in their favor, one can be optimistic about their case. This is great news for Pfizer, given the revenue generated from the sale of the drug Eliquis. Last year, Pfizer reported more than $4.9 billion in revenue from the alliance and direct sales of the drug Eliquis. That's a 17% increase over the previous year. And this was during a pandemic when access to non-COVID health care was limited. Eliquis continues to be one of Pfizer's biggest drugs. In the second quarter of this year, Eliquis generated more than $1.4 billion in revenue. That's a 16% increase over the previous year, and Eliquis was Pfizer's second-largest drug after the coronavirus vaccine. Of course, generic competition will eventually lead to lower sales of this blockbuster drug. But the court ruling gives Pfizer seven years to develop products that can replace Eliquis as a major source of revenue. Pfizer has a lot of development going on. One of the most interesting candidates is an oral drug to treat the coronavirus. It would be a pill that people could take within days of the first symptoms, and it could be a game-changer and generate billions of dollars in revenue. Pfizer began Phase 2/3 trials in July and plans to present data in the fourth quarter. The company also recently began a Phase 3 trial of a vaccine candidate against respiratory syncytial infection. Currently, there is no vaccine against this common cause of severe respiratory disease. Should you buy Pfizer stock because of news about the Eliquis patent? It's not the only reason to buy the stock, but it's one great reason. Add to that the recurring earnings from the coronavirus program. And let's not forget the company's other blockbusters. Let's not forget the drugs and vaccines that could bring in a lot of revenue in the future. All of this together is a solid recipe for success over time. Pfizer stock is up 25% and is currently outperforming the S&P 500 Index. However, the stock is hardly reflective of all the positives now and in the future. They are trading at 11 times earnings estimates. By that measure, the stock is cheap today. Pfizer stock is far behind biotech players in the coronavirus vaccine space such as its own partner BioNTech and rival Moderna. You can't be sure that the situation will change. It's much easier to quickly raise the price of a company with less market value than a major pharmaceutical player. But over time, Pfizer has serious potential to increase revenues and profits -- and that should match the stock's rise. This month's news on the Eliquis patent is a huge step in the right direction.
NYSE:PFELong
by FOREXN1
4
$PFE - Key Levels and Analysis - REQUEST - I hold no position$PFE - Key Levels and Analysis ————— @Smartdaytrading, I think that PFE is overdue for a trip back toward the 180EMA(Purple)… Right now it is sitting right under the 35 EMA (Red) and this week if it closes under the gray line right under the red then I’d say watch for 41.64… that would be a good place to add if you’re long… The 35EMA has held as support for a large part of this year, but it tends to become resistance once it crosses down (and actually closes with the entire candle under the 35EMA)… and it’s been a little too long since it’s corrected back to the 180… Anything can happen... but I'd say keep a close eye on 41-42 area —————— I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Red = Resistance Green = Support Blue = trendlines Have fun, y’all!!
NYSE:PFE
by SPYder_QQQueen_Trading
7
WE'D FACE THE BEARISH ABC CORRECTION 💉✅PREVIOUSLY ON PFE It can be thought that the 3rd wave finished at 51.86. ✅ WHERE WE ARE We could be on the correction waves. If 45.42 is A, the price falls to break A(45.42) After B hits. As of now, 43.27(Fib61.8) looks like the beginning of the next bullish impulse, circled 4. *As long as 51.86 remains unbroken, this idea is valid. 💡The absolute principle for trading💡 BUY - as low as possible SELL - as high as possible PLEASE DO NOT FORGET TO SMASH LIKE👍🏻 AND FOLLOW ME❤ IT MOTIVATES ME TO THE NEXT IDEA! THANK YOU 🎉
NYSE:PFEShort
by waveslover
2
PFE STILL MORE GAS IN THE TANKThis chart has been fairly predictable for the past year, however as we start to shape up the larger degree wave count, I've decided to alter this from an expanding diagonal to a typical impulse. The main thing shaping this is the action for wave 2 which appears to be a flat. Under this premise, we have subdivision of wave 3 underway. It appears to be an expanded third: triggering the 1.618 with evidence of another leg up to the 2.272 at $56. This is the primary trade at hand, as we target 15-20% gains here. This trade presents a 10:1 RR with a SL around $45.50 at the recent low for a 20% target. Wave 4 of 3 looks to be complete, hitting the 1.618 extension of A to B (see chart below). We have RSI testing the 70 which will be telling: if it can get into overbought territory, then it's indication of a trend reversal (as markets typically only go into overbought when bullish). Not pictured is the stacking bullish divergence for this wave 4. Another thing that stands out as evidence of wave 4 complete is that it was sharper than wave 2 of 3. By rule of alternation, we would expect this. Upon hitting this target near $56, we will reevaluate, likely close, and look for the next wave down. For now, I have a $45 level identified (w4 larger count) and a 2.618 target near $60 (w5 larger count) on the map. Remember: for extended wave 3s that approach the 2.0, we look for the next fib level near 2.618 for w5. These future targets are dependent on what happens here in this wave 3.
NYSE:PFELong
by warrenbudget
9
$PFE Long term PT 300 and higher$PFE Lepas Calls 70 Jun 16th 2023 Returns +10,125% $BNTX and $PFE Leaps The FDA approval of Pfizer’s COVID-19 vaccine is a ‘critical step forward in vaccine confidence’: Doctor Army gives Pfizer $3.5B contract to make 500 million COVID vaccine doses Pfizer authorizes $1 billion for oral COVID-19 treatment, CEO says Pfizer now expects its Covid vaccine to generate $33.5 billion in full-year sales, the company said Wednesday. Pfizer Is Ready, Even For COVID-19 Variants CDC NOW ADVISING STATES TO PREPARE TO DISTRIBUTE THE COVID-19 VACCINE AS SOON AS LATE OCTOBER
NYSE:PFELong
by BADQOMOCAWGOWLD
1